Camurus
Developing and commercializing innovative and long-acting medicines.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| N/A | €68.9m Valuation: €216m | IPO | |
| Total Funding | 000k | ||
| SEK | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 79 % | 59 % | 80 % | 9 % | 47 % | 56 % | 35 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (16 %) | 8 % | 33 % | 30 % | 40 % | 50 % | 59 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (15 %) | 6 % | 25 % | 23 % | 33 % | 42 % | 49 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 65 % | 50 % | 37 % | 37 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Camurus is a pharmaceutical company dedicated to improving the lives of patients with severe and chronic diseases. The company operates in the healthcare sector, focusing on developing and commercializing innovative treatments for conditions within the central nervous system (CNS), rare diseases, endocrinology, oncology, and supportive care. Camurus serves a diverse range of clients, including healthcare providers, hospitals, and specialty clinics. The company’s business model revolves around research and development (R&D) of advanced drug delivery technologies and formulations, which are then brought to market through a combination of in-house commercialization and strategic partnerships. Revenue is generated primarily through product sales, licensing agreements, and milestone payments from collaborations. Camurus leverages its proprietary FluidCrystal® technology to create long-acting injectable treatments that improve patient adherence and outcomes. The company is headquartered in Lund, Sweden, and operates globally, with a strong presence in Europe and expanding markets in North America and Asia.
Keywords: CNS treatments, rare diseases, endocrinology, oncology, supportive care, FluidCrystal® technology, long-acting injectables, patient adherence, pharmaceutical R&D, global healthcare.